Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. AU2011311255 - Method for increasing permeability of an epithelial barrier

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]
60
CLAIMS:
1.         A method for increasing the permeability of a cellular layer that comprises epithelial cells, the method comprising contacting the cellular layer with a microneedle, wherein a plurality of nanostructures are formed on a surface of the microneedle in a predetermined pattern, at least a portion of the nanostructures having a cross-sectional dimension of from about 5 nanometers to 500 nanometers, wherein subsequent to contact between the cellular layer and the microneedle, the cellular layer exhibits increased permeability to a drug compound.
2.         The method according to claim 1, wherein subsequent to contact between the cellular layer and the microneedle, the transepithelial electrical resistance of the cellular layer is less than about 95% of the transepithelial electrical resistance of the layer prior to contact with the microneedle.
3.         The method according to claim 1, wherein subsequent to the contact between the cellular layer and the microneedle, the transepithelial electrical resistance of the cellular layer is less than about 85%, of the transepithelial electrical resistance of the layer prior to contact with microneedle.
4.         The method according to claim 1, wherein subsequent to the contact between the cellular layer and the microneedle, the transepithelial electrical resistance of the cellular layer is less than about 70% of the transepithelial electrical resistance of the layer prior to contact with the microneedle.
5.         The method according to any one of the preceding claims, wherein the pattern further includes microstructures, wherein the nanostructures have a crosssectional dimension smaller than the microstructures.
6.         The method of claim 5, further comprising second nanostructures having a cross-sectional dimension less than the cross-sectional dimension of the microstructures and greater than the cross-sectional dimension of the first nanostructures.
7.         The method according to any one of the preceding claims, wherein the cellular layer is skin.
8.         The method according to any one of the preceding claims, the method changing the structure of an intercellular junction.
9.         The method according to claim 8, wherein the intercellular junction is a tight junction.
61
10.       The method according to any one of the preceding claims, further comprising delivering the drug compound across the cellular layer.
11.       The method according to claim 10, wherein the drug compound is a protein therapeutic. 12. The method according to claim 11, wherein the drug compound has a molecular weight greater than about 100 kDa.
13.       The method according to any one of the preceding claims, wherein the drug compound permeates across the cellular layer via paracellular transport.
14.       The method according to any one of the preceding claims, wherein the drug compound permeates across the cellular layer via transcellular transport.
15.       The method according to any one of the preceding claims, wherein the device includes a reservoir for holding the drug compound.
16.       The method according to claim 1, wherein at least a portion of the nanostructures have an aspect ratio of from about 0.15 to 30.
17.       The method according to claim 1, wherein the pattern has a fractal dimension of greater than about 1.
18.       The method according to claim 1, wherein at least a portion of the nanostructures have a cross-sectional dimension of from about 100 to 300 nanometers.
19.       The method according to claim 1, wherein the nanostructures have approximately the same cross-sectional dimension.
20.         The method according to claim 1, wherein at least a portion of the nanostructures have a center-to-center spacing of from about 50 nanometers to 1 micrometer.
21.       The method according to claim 1, wherein the ratio of the cross sectional dimension of two adjacent nanostructures to the center-to-center spacing between those two structures is between about 1:1 and 1:4.
22.       The method according to claim 1, wherein at least a portion of the nanostructures have an equidistant spacing.
23.       The method according to claim 1, wherein at least a portion of the nanostructures have a height of from about 10 nanometers to 1 micrometer.
62
24.       The method according to claim 1, wherein at least a portion of the nanostructures have an aspect ratio of from about 0.15 to 30.
25.       The method according to claim 1, wherein the nanostructures are in the form of pillars. 26. The method according to claim 11, wherein the drug compound is a TNF-a blocker. 27. The method according to claim 1, wherein the microneedle contains a channel for delivering the drug compound.
Kimberly-Clark Worldwide, Inc.
Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON